A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated t

Cancer

Volumn 121, Issue 16, 2015, Pages 2749-2756

  Cabanillas, Maria E ^a   Schlumberger, Martin ^b   Jarzab, Barbara ^c   Martins, Renato G ^d   Pacini, Furio ^e   Robinson, Bruce ^f   McCaffrey, Judith C ^g   Shah, Manisha H ^h   Bodenner, Donald L ⁱ   Topliss, Duncan ^j   Andresen, Corina ^k   O'Brien, James P ^k   Ren, Min ^k   Funahashi, Yasuhiro ^k   Allison, Roger ^l   Elisei, Rossella ^m   Newbold, Kate ⁿ   Licitra, Lisa F ^o   Sherman, Steven I ^a   Ball, Douglas W ^p  

^a UNIVERSITY OF TEXAS   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SIENA   (Italy)

^f University of Sydney   (Australia)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^j ALFRED HOSPITAL   (Australia)

^k EISAI INC   (United States)

^l ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^m UNIVERSITY OF PISA   (Italy)

ⁿ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^o NATIONAL CANCER INSTITUTE   (Italy)

^p JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

biomarkers; differentiated thyroid cancer; lenvatinib; multikinase inhibitor; phase 2; radioiodine refractory

Indexed keywords

LENVATINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; RADIOACTIVE IODINE; TUMOR MARKER;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CANCER SURVIVAL; CLINICAL ASSESSMENT; COUGHING; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPHORIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEADACHE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOTENSION; LIMB PAIN; LOWER ABDOMINAL PAIN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; OVERALL SURVIVAL; PATIENT MONITORING; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIOISOTOPE THERAPY; SKIN DISEASE; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VOMITING; XEROSTOMIA; CLINICAL TRIAL; DISEASE COURSE; MIDDLE AGED; MORTALITY; THYROID NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; QUINOLINES; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84938744059     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29395     Document Type: Article

References (36)

1. Busaidy NL, Cabanillas ME,. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease [serial online]. J Thyroid Res. 2012; 2012: 618985.
2. National Cancer Institute; Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Statistics Factsheets. Thyroid Cancer. Bethesda, MD: National Cancer Institute; 2014. http://seer.cancer.gov/statfacts/html/thyro.html. Accessed April 9, 2014.
3. DeLellis RA, Lloyd R, Heitz P, Eng C, eds. Pathology and Genetics of Tumours of Endocrine Organs. IARC World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2004.
4. Links TP, van Tol KM, Jager PL, et al., Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer. 2005; 12: 273-280.
5. Durante C, Haddy N, Baudin E, et al., Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006; 91: 2892-2899.
6. Pacini F, Castagna MG, Brilli L, Pentheroudakis G,; on behalf of ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 (suppl 7): vii110-vii119.
7. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 2.2013. Fort Washington, PA: NCCN; 2013.
8. Sherman SI,. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010; 22: 464-468.
9. Schlumberger M, Sherman SI,. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol. 2012; 166: 5-11.
10. Klein M, Vignaud JM, Hennequin V, et al., Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2001; 86: 656-658.
11. Sherman SI,. Targeted therapies for thyroid tumors. Mod Pathol. 2011; 24 (suppl 2): S44-S52.
12. Gild ML, Bullock M, Robinson BG, Clifton-Bligh R,. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol. 2011; 7: 617-624.
13. Brose MS, Nutting C, Jarzab B, et al., Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract 4.
14. Bass MB, Sherman SI, Schlumberger MJ, et al., Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab. 2010; 95: 5018-5027.
15. Broutin S, Ameur N, Lacroix L, et al., Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models. Clin Cancer Res. 2011; 17: 2044-2054.
16. Matsui J, Yamamoto Y, Funahashi Y, et al., E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008; 122: 664-671.
17. Okamoto K, Kodama K, Takase K, et al., Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013; 340: 97-103.
18. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M,. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008; 14: 5459-5465.
19. Matsui J, Minoshima Y, Tsuruoka A, Funahashi Y,. Multi-targeted kinase inhibitor E7080 showed anti-tumor activity against medullary thyroid carcinoma and squamous thyroid carcinoma cell line based on RET and VEGFR2 tyrosine kinase inhibition [abstract]. Cancer Res. 2010; 70 (8 suppl 1). Abstract 3614.
20. Boss DS, Glen H, Beijnen JH, et al., A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012; 106: 1598-1604.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
22. Cohen EE, Rosen LS, Vokes EE, et al., Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008; 26: 4708-4713.
23. Sherman SI, Wirth LJ, Droz JP, et al., Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008; 359: 31-42.
24. Bible KC, Suman VJ, Molina JR, et al., Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010; 11: 962-972.
25. Leboulleux S, Bastholt L, Krause T, et al., Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012; 13: 897-905.
26. Carr LL, Mankoff DA, Goulart BH, et al., Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010; 16: 5260-5268.
27. Jonklaas J, Nogueras-Gonzalez G, Munsell M, et al., The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 2012; 97: E878-E887.
28. Vini L, Harmer C,. Management of thyroid cancer. Lancet Oncol. 2002; 3: 407-414.
29. Kloos RT, Ringel MD, Knopp MV, et al., Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009; 27: 1675-1684.
30. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J,. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010; 28: 2280-2285.
31. Ferrara N, Kerbel RS,. Angiogenesis as a therapeutic target. Nature. 2005; 438: 967-974.
32. Huang H, Bhat A, Woodnutt G, Lappe R,. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010; 10: 575-585.
33. Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE,. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013; 73: 1649-1657.
34. Bullock AJ, Zhang L, O'Neill AM, et al., Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC) [abstract]. J Clin Oncol. 2010; 28 (15 suppl). Abstract 4630.
35. Rini BI, Atkins MB,. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009; 10: 992-1000.
36. Schlumberger M, Tahara M, Wirth LJ, et al., Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015; 372: 621-630.